LakeShore Net Income From Continuing Ops from 2010 to 2026

LSBCF Stock   0.26  0.14  35.00%   
LakeShore Biopharma's Net Loss is decreasing over the last several years with stable swings. Net Loss is predicted to flatten to about -94.5 M. During the period from 2010 to 2026 LakeShore Biopharma Co Net Loss regressed destribution of quarterly values had mean deviationof  38,554,698 and mean square error of 6450.1 T. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-90 M
Current Value
-94.5 M
Quarterly Volatility
80.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 38.4 M, Interest Expense of 27.1 M or Selling General Administrative of 134.5 M, as well as many indicators such as Price To Sales Ratio of 3.38, Dividend Yield of 0.0 or PTB Ratio of 4.16. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Build AI portfolio with LakeShore Stock
Check out the analysis of LakeShore Biopharma Correlation against competitors.
The Net Income From Continuing Ops trend for LakeShore Biopharma Co offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether LakeShore Biopharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest LakeShore Biopharma's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of LakeShore Biopharma Co over the last few years. It is LakeShore Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

LakeShore Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(125,614,521)
Coefficient Of Variation(63.77)
Mean Deviation38,554,698
Median(106,004,401)
Standard Deviation80,108,048
Sample Variance6417.3T
Range343.5M
R-Value(0.24)
Mean Square Error6450.1T
R-Squared0.06
Significance0.35
Slope(3,810,687)
Total Sum of Squares102676.8T

LakeShore Net Income From Continuing Ops History

2026-94.5 M
2025-90 M
2024-100 M
2023-433.5 M
2022-145.5 M

About LakeShore Biopharma Financial Statements

LakeShore Biopharma stakeholders use historical fundamental indicators, such as LakeShore Biopharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although LakeShore Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in LakeShore Biopharma's assets and liabilities are reflected in the revenues and expenses on LakeShore Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in LakeShore Biopharma Co. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-90 M-94.5 M

Currently Active Assets on Macroaxis

When determining whether LakeShore Biopharma is a strong investment it is important to analyze LakeShore Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact LakeShore Biopharma's future performance. For an informed investment choice regarding LakeShore Stock, refer to the following important reports:
Check out the analysis of LakeShore Biopharma Correlation against competitors.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Can Biotechnology industry sustain growth momentum? Does LakeShore have expansion opportunities? Factors like these will boost the valuation of LakeShore Biopharma. Expected growth trajectory for LakeShore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating LakeShore Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding LakeShore Biopharma requires distinguishing between market price and book value, where the latter reflects LakeShore's accounting equity. The concept of intrinsic value - what LakeShore Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push LakeShore Biopharma's price substantially above or below its fundamental value.
Understanding that LakeShore Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LakeShore Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LakeShore Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.